



## Microbial Glycans As A Target Of Human Intelectin

[View U.S. Patent No. 10,082,506 in PDF format.](#)

**WARF: P150027US02**

Inventors: Laura Kiessling, Darryl Wesener, Kittikhun Wangkanont

---

### The Invention

The present disclosure provides for methods of diagnosing and treating bacterial infections. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria including *Streptococcus pneumonia*, *Proteus mirabilis*, *Proteus vulgaris*, *Klebsiella pneumonia* and *Yersinia pestis*. This interaction can be targeted to identify, purify and therapeutically target such organisms.

#### Tech Fields

- [Diagnostics & Biomarkers : Diagnostics](#)
- [Drug Delivery : Other drug delivery technologies](#)
- [Research Tools : Detection](#)

For current licensing status, please contact Rafael Diaz at [rdiaz@warf.org](mailto:rdiaz@warf.org) or 608-960-9847